Biomarin Pharmaceutical Inc. (BMRN)

BMRN (NASDAQ:Drugs)
$60.89
pos +0.00
+0.00%
Today's Range: 60.50 - 62.61 | BMRN Avg Daily Volume: 1,626,100
Last Update: 04/17/14 - 3:59 PM EDT
Volume: 0
YTD Performance: -13.45%
Open: $0.00
Previous Close: $61.37
52 Week Range: $53.53 - $84.25
Oustanding Shares: 143,623,224
Market Cap: 8,745,218,109
6-Month Chart
TheStreet Ratings Grade for BMRN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 11 11 11
Moderate Buy 0 0 0 0
Hold 6 6 6 6
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.75 1.71 1.71 1.71
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -63.43
Price Earnings Comparisons:
BMRN Sector Avg. S&P 500
-63.43 0.00 29.08
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-17.10% -4.38% 127.54%
GROWTH 12 Mo 3 Yr CAGR
Revenue 9.50 0.46 0.13
Net Income 0.00 -1.86 0.00
EPS 0.00 -1.64 0.00
Earnings for BMRN:
EBITDA -0.10B
Revenue 0.55B
Average Earnings Estimates
Qtr (03/14) Qtr (06/14) FY (12/14) FY (12/15)
Average Estimate $-0.49 $-0.48 $-1.78 $-1.12
Number of Analysts 9 9 11 11
High Estimate $-0.37 $-0.32 $-1.24 $-0.46
Low Estimate $-0.62 $-0.59 $-2.06 $-1.45
Prior Year $-0.31 $-0.16 $-0.76 $-1.78
Growth Rate (Year over Year) -56.63% -200.00% -133.85% 37.19%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Apr 16, 2014 | 11:45 AM EDT

Algos think faster and react faster than humans can.

By

Jim Cramer

 | Apr 14, 2014 | 11:49 AM EDT

Cautionary tales that the IPO window might be closing at last.

By

Jim Cramer

 | Mar 25, 2014 | 7:20 AM EDT

In other words, wait for the downgrades.

bullishBioMarin Pharma price target lifted at Jefferies

Feb 19, 2014 | 7:51 AM EST

BMRN raised its number, according to Jefferies. Valuation call driven by success of 3 Ph3 products. $87 price target and Buy rating. 

bearishBiomarin downgraded at Stifel

Sep 18, 2013 | 8:10 AM EDT

BMRN was downgraded from Buy to Hold, Stifel Nicolaus said. Valuation call, as the stock is largely pricing in potential near-term catalysts. 

bullishBioMarin estimates raised at UBS

Jul 26, 2013 | 8:16 AM EDT

BMRN estimates were raised to reflect the earnings beat, said UBS. Price target is $67.

By

Jim Cramer

 | Jun 3, 2013 | 11:25 AM EDT

Jim Cramer looks at stocks moving on cancer-fighting develompents, in a discussion with Mad Money Research Director Nicole Urken

bullishBioMarin Pharmaceutical price target raised at Citi

May 31, 2013 | 7:59 AM EDT

BMRN price target was raised to $79 as anti-cancer drug BMN-673 was included in the model, said Citigroup.

updateBiomarin rated new Neutral at Credit Suisse

May 31, 2013 | 7:22 AM EDT

BMRN was initiated with a Neutral rating, Credit Suisse said. Valuation call, based on a $68 price target. 

By

Jim Cramer

 | Apr 2, 2013 | 11:58 AM EDT

Jim Cramer discusses hyper growth names with safety in discussion with Mad Money Research Director Nicole Urken

The new Fed Chief said this at a recent meeting of the Economic Club of NY ... "We have in...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.